Provided by Tiger Trade Technology Pte. Ltd.

DUALITYBIO-B

198.300
+15.0008.18%
Volume:1.07M
Turnover:206.52M
Market Cap:18.01B
PE:-4.25
High:200.200
Open:183.700
Low:183.700
Close:183.300
52wk High:493.800
52wk Low:158.500
Shares:90.83M
HK Float Shares:90.83M
Volume Ratio:1.88
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-46.628
ROE:-65.93%
ROA:-24.28%
PB:10.60
PE(LYR):-4.25
PS:18.26

Loading ...

DUALITYBIO-B Surges Nearly 6% Following Genentech Licensing Pact

Deep News
·
Aug 28

Movement Alert|DUALITYBIO-B Rises 5.27% in Regular Trading, Signs Global ADC R&D Collaboration with Genentech Securing $45M Upfront Payment

Market Focus
·
Aug 28

Hong Kong Market Movers: Mixue's Revenue Reaches RMB 15.2 Billion in First Half, Global Store Network Expands

Stock News
·
Aug 28

DUALITYBIO-B Inks Landmark Global ADC Collaboration with Roche's Genentech Using Proprietary DUPAC Platform

Stock News
·
Aug 28

DualityBio Signs US$45.00 Million Upfront Collaboration With Genentech to Advance DUPAC-Based Next-Generation ADCs

Bulletin Express
·
Aug 28

Duality Biotherapeutics Inc - Global Research and Development Collaboration and License Agreement with Genentech

THOMSON REUTERS
·
Aug 28

Duality Biotherapeutics - Genentech to Obtain Exclusive Worldwide License to Collaboration Antibody-Drug Conjugates

THOMSON REUTERS
·
Aug 28

Duality Biotherapeutics - Dualitybio-B to Receive Upfront Payment of US$45 Mln Under Collaboration Agreement

THOMSON REUTERS
·
Aug 28

Duality Biotherapeutics Signs Genentech Pact for Next-Generation ADCs, Gets US$45 Million Upfront

Reuters
·
Aug 28

HK Movers | Biotech Stocks Jump. CANSINOBIO Surges 17%; Innovent Bio up 11%; Akeso up over 8%; Everest Med up 7%

Tiger Newspress
·
Aug 26

Movement Alert|DUALITYBIO-B Rises 5.12% in Regular Trading, Innovative Drug Sector Rally and Interim Results Approaching

Market Focus
·
Aug 25

Earning Preview: DUALITYBIO-B revenue outlook undisclosed and institutions tilt bullish

Earnings Agent
·
Aug 21

Movement Alert|DUALITYBIO-B Rises 5.22% in Regular Trading, UBS Initiates Coverage with Buy Rating as Interim Results Approach

Market Focus
·
Aug 21

Movement Alert|DUALITYBIO-B Rises 5.56% in Regular Trading, UBS Initiates Coverage with Buy Rating Amid Sector Strength

Market Focus
·
Aug 20

UBS Initiates Coverage on DUALITYBIO-B with "Buy" Rating and HK$320 Target Price

Deep News
·
Aug 17

Movement Alert|DUALITYBIO-B Falls 5.14% in Regular Trading, Biotech Sector Under Pressure Amid BioNTech Partnership Uncertainty

Market Focus
·
Aug 17

Everest Medicines Appoints Yue Wang as Non-Executive Director

Reuters
·
Aug 14

Duality Biotherapeutics Schedules 28 Aug 2026 Board Meeting to Review 1H 2026 Unaudited Results

Bulletin Express
·
Aug 14

Movement Alert|DUALITYBIO-B Rises 5.28% in Regular Trading, Biotech Sector Rally Extends Valuation Recovery

Market Focus
·
Aug 11

Movement Alert|DUALITYBIO-B Rises 5.09% in Regular Trading, Biotech Sector Strength Drives Rebound Continuation

Market Focus
·
Aug 07